Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05908864 |
Other study ID # |
#FWA00015574 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 30, 2018 |
Est. completion date |
December 15, 2020 |
Study information
Verified date |
June 2023 |
Source |
Beni-Suef University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
A prospective study in Beni-Seuf University Hospital that was conducted on 123 adult patients
with acute asthma exacerbations. Patients were classified into group (I): received IV
magnesium sulfate, group (II): received nebulized magnesium sulfate, and group (III): control
group. Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement
using a peak flowmeter, Fischl index and need for hospitalization in patients with acute
bronchial asthma were done for all patients before treatment, immediately after the
treatment, "30", and "60" min after treatment.
Description:
Inclusion criteria :
- adult patients between the ages of 18 and 50 years with acute attack of bronchial asthma
- from both sexes
- Normal renal function
- Normal cardiovascular function
Exclusion criteria:
- Patients were younger than 18 years or older than 50 years.
- Patients suffered from chronic obstructive pulmonary disease, renal disorder and heart
failure
All patients were subjected to: complete history taking, blood sampling for serum magnesium
measurement (on admission before the initial treatment and after the initial treatment) the
patients were randomly separated into 3 equal groups each group consists of 41 patients.
The 1ST group has been managed by an initial treatment plan (consists of supplemental oxygen
therapy to keep oxygen saturation higher than 90%., nebulization of 1 ml salbutamol
respirator solution mixed with 9 ml normal saline solution for one session [Farcolin
respirator solution: each 20 ml of Farcolin contains Salbutamol sulfate 0.121 gm. Made in
Egypt, by: Pharco Pharmaceuticals -Alexandria], Intravenous administration of hydrocortisone
100 mg for a single dose [Solu-Cortef: vial contains powder of 100 mg Sodium hydrocortisone
sodium succinate dissolved with 2 ml solvent of sterile bacteriostatic water for IV
injection. Manufactured by: Egyptian Int. Pharmaceutical Industries co. (e.i.p.i.co.) -
Egypt. Under license of: Pfizer]) plus a single dose (2000 mg) of magnesium sulfate prepared
by mixing 20 ml of 10 % magnesium sulfate (2000 MG) [14] ,manufactured by Memphis
Pharmaceuticals and Chemical Industries, with 30 ml of distillated water for injection to
produce 50 ml of isotonic magnesium sulfate solution (324 MSOM/L) administered intravenously
over 1 hour.
The 2nd group has been managed by the same initial treatment plan plus a single dose (2000
mg) of magnesium sulfate prepared by mixing 20 ml of 10 % magnesium sulfate (2000 MG) [14]
,manufactured by Memphis Pharmaceuticals and Chemical Industries, with 30 ml of distillated
water to produce 50 ml of isotonic magnesium sulfate solution (324 MSOM/L). nebulized using
jet nebulizer over 1 hour.
The 3rd group has been managed by the same treatment plan Without using magnesium sulfate. (a
control group) the following were recorded for each patient at a fixed interval (before the
initial treatment, immediately after the initial treatment, 30, and 60 min after the initial
treatment):
1. blood pressure, respiratory rate and pulse rate
2. Peak expiratory flow measurement using peak flow meter.
3. Fischl index for relapse and need for hospitalization in patients with acute bronchial
asthma. [16[ .